Celldex Therapeutics to Present at Upcoming Investor Conferences
Celldex Therapeutics, Inc. (NASDAQ: CLDX) had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $42.00 to $36.00. They now have a "neutral" rating on the stock.
Celldex Therapeutics Presents Positive Preclinical Data from Inflammatory Bispecific Antibody Program CDX-622 at AAAAI 2025
Celldex Therapeutics Full Year 2024 Earnings: Revenues Beat Expectations, EPS In Line [Yahoo! Finance]
Celldex Therapeutics Presents Positive Results from Barzolvolimab Phase 2 Studies in Patients with Chronic Urticaria Demonstrating Improved Disease Control and Quality of Life at AAAAI 2025